The Cystic Fibrosis Foundation today announced an unprecedented acceleration and expansion of its research, care and patient programs for the CF community. This action is possible as a result of the sale of the Foundation's royalty rights to CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation received $3.3 billion from the sale to Royalty Pharma.
Site Search
Showing 51 - 54 of 54 results
News
|
|
3 min read
The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.
News
|
|
1 min read
News
|
|
1 min read
In addition to the typical travel headaches, people with cystic fibrosis must also consider other things related to their health. This section will discuss ways to be as prepared as possible for your trip so that you can spend less time on travel hassles and more time enjoying yourself.